Bayer Aktiengesellschaft (BAYRY)

Healthcare
Drug Manufacturers - General
Germany
Yahoo Finance  •  Trading View  •  Company site
Price
$7.89
▲ 0.00 (0.00%)
Market Cap
$31,053,701,120
Shares: 982,420,000
P/E
-7.43
P/B: 0.59
ROE
-8.00%
Current Ratio: 1.19
Fundamentals Score
67 (NEUTRAL)

Company Overview

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, pain and cardiovascular risk prevention products, digestive health products, allergy products, and cold and cough products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Headquarters: Kaiser-Wilhelm-Allee 1, Leverkusen, 51368, Germany  |  Employees: 89556  |  Website: bayer.com
Key Contacts
IR / Phone: 49 214 30 1
Exchange: OQX
Industry: Drug Manufacturers - General
Quick Financial Snapshot
Revenue$46,606,000,000
Net Income$-2,552,000,000
Free Cash Flow$4,590,000,000
Book Value / Share$32.62

Balance Sheet & Liquidity

Total Liabilities$78,805,000,000
Total Equity$31,908,000,000
Debt / Equity1.28
Current Ratio1.19
Interest Coverage2.29
Working Capital$5,492,000,000

Valuation Metrics

Core multiples and valuation signals — useful to compare vs peers.

P/E (TTM)-7.43
Industry P/EN/A
Forward P/E5.40
P/B0.59
Price / Sales0.41
P / FCF4.13
EV / EBITDA14.08
Graham NumberN/A
DCF (placeholder)
Notes: red items typically indicate expensive multiples relative to fundamentals. Use the "Compare with industry" tool for context.

EPS (Annual)

Financial Performance

Revenue vs Net Income

Free Cash Flow (annual)

Profitability & Efficiency

Gross Margin 54.36%
Operating Margin 9.61%
Net Margin -5.48%
ROIC 5.60%
Asset Turnover 0.42

Automated Fundamental Signals (Score: 67)

Passed
  • EPS shows upward trend
  • ROIC 5.6%
  • Gross Margin 54.4%
  • P/FCF 4.13
  • P/B Ratio 0.59
  • Debt/Equity ratio
  • Operating Margin 7.1%
  • Positive Free Cash Flow
  • Current Ratio
  • Interest Coverage
  • DCF valuation (Undervalued)
Failed
  • Price CAGR -12.85%
  • CapEx intensity
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles

Price Chart (Candlestick)

Technical Analysis (Score: 65)

RSI (14)43.15
SMA 508.06
SMA 2006.94
MACD-0.04
Signal NEUTRAL
RSI 43.1, SMA trend bullish, momentum 10.7%.

Governance & Management

Governance scores: Audit: N/A | Board: N/A | Compensation: N/A | Shareholder Rights: N/A
Executive Team
NameTitle
Mr. William N. Anderson Chairman of the Management Board & CEO (1966)
Mr. Wolfgang U. Nickl CFO & Member of Management Board (1969)
Mr. Stefan Oelrich Head of the Pharmaceuticals Division & Member of the Board of Management (1968)
Mr. Rodrigo Santos Member of Management Board & President of the Crop Science Division (1973)
Ms. Heike Prinz Chief Talent Officer, Labor Director & Member of Management Board (1964)
Mr. Julio Triana Member of Management Board & President of Consumer Health Division (1965)
Dr. Sebastian Guth Ph.D. COO & Head of Commercial Operations Americas of Pharmaceutical (—)
Ms. Amanda McClerren Chief Information Officer, Head-Digital Transformation & IT-Crop Science Division (—)
Governance data last updated: N/A

Latest News

No news available for this company.

← Back